Oliver Degerstedt

Mr. Oliver Degerstedt

Uppsala University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
FKFredrik Kullenberg
Fredrik Kullenberg
Oliver DegerstedtOliver Degerstedt
Oliver Degerstedt
CCCarlemi Calitz
Carlemi Calitz
NPNatasa Pavlovic
Natasa Pavlovic
David BalgomaDavid Balgoma
David Balgoma
HLHans Lennernäs
Hans Lennernäs
Cytostatic effects of doxorubicin in clinically applied doses are often inadequate and limited by systemic toxicity. The main objective of this in vitro study was to determine the anti-tumoral effect (IC50) and intracellular accumulation of free and liposomal doxorubicin (DOX) in four human cancer cell lines (HepG2, Huh7, SNU449 and MCF7). The results of this study showed a correlation between longer DOX exposure time and lower IC50 values, which can be attributed to an increased cellular uptake and intracellular exposure of DOX, ultimately leading to cell death. We found that the total intracellular concentrations of DOX were a median value of 230 times higher than the exposure concentrations after exposure to free DOX. The intracellular uptake of DOX from solution was at least 10 times higher than from liposomal formulation. A physiologically based pharmacokinetic model was developed to translate these novel quantitative findings to a clinical context and to simulate clinically relevant drug concentration–time curves. This showed that a liver tumor resembling the liver cancer cell line SNU449, the most resistant cell line in this study, would not reach therapeutic exposure at a standard clinical parenteral dose of doxorubicin (50 mg/m2), which is serious limitation for this drug. This study emphasizes the importance of in-vitro to in-vivo translations in the assessment of clinical consequence of experimental findings.

26 February 2022 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
Oliver DegerstedtOliver Degerstedt
Oliver Degerstedt
JGJohan Gråsjö
Johan Gråsjö
ANAnton Norberg
Anton Norberg
ESErik Sjögren
Erik Sjögren
PHPer Hansson
Per Hansson
HLHans Lennernäs
Hans Lennernäs
Hydrogels of varying complexity are routinely used as scaffolds and 3D structures for in vitro tumor models to increase physiological relevance within pre-clinical cancer research. Relatively simple hydrogels such as agarose are well characterised, meanwhile biomimetic gels containing collagen and fibrin(ogen) have been studied to a much lesser extent. In this study, hydrogels mimicking the biophysical characteristics of liver cancer progression were investigated in terms of their UV-properties and influence on diffusion coefficients of different substances. UV-imaging technology was used to both visualize and quantify the diffusion process in a simple and rapid way. In general, agarose gel diffusion agreed well with predictions using the Stokes-Einstein equation meanwhile the biomimetic gels reduced diffusion coefficients by up to 70%. For doxorubicin, spatio-temporal tissue concentration modelling was used to translate in vitro diffusion to the more clinical context of tumor penetration in a solid liver tumor supplied by arterial blood.

1 October 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
EAEmelie Ahnfelt
Emelie Ahnfelt
Oliver DegerstedtOliver Degerstedt
Oliver Degerstedt
ELElsa Lilienberg
Elsa Lilienberg
ESErik Sjögren
Erik Sjögren
PHPer Hansson
Per Hansson
HLHans Lennernäs
Hans Lennernäs

22 October 2022 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
FKFredrik Kullenberg
Fredrik Kullenberg
KPKarsten Peters
Karsten Peters
CLC. Luna-Marco
C. Luna-Marco
ASA. Salomonsson
A. Salomonsson
MKM. Kopsida
M. Kopsida
HLHans Lennernäs
Hans Lennernäs
Chemotherapy-induced intestinal mucositis is a severe side effect contributing to reduced quality of life and premature death in cancer patients. Despite a high incidence, a thorough mechanistic understanding of its pathophysiology and effective supportive therapies are lacking. The main objective of this rat study was to determine how 10 mg/kg doxorubicin, a common chemotherapeutic, affected jejunal function and morphology over time (6, 24, 72, or 168 h). The secondary objective was to determine if the type of dosing administration (intraperitoneal or intravenous) affected the severity of mucositis or plasma exposure of the doxorubicin. Morphology, proliferation and apoptosis, and jejunal permeability of mannitol were examined using histology, immunohistochemistry, and single-pass intestinal perfusion, respectively. Villus height was reduced by 40% after 72 h, preceded at 24 h by a 75% decrease in proliferation and a sixfold increase in apoptosis. Villus height recovered completely after 168 h. Mucosal permeability of mannitol decreased after 6, 24, and 168 h. There were no differences in intestinal injury or plasma exposure after intraperitoneal or intravenous doxorubicin dosing. This study provides an insight into the progression of chemotherapy-induced intestinal mucositis and associated cellular mucosal processes. Knowledge from this in vivo rat model can facilitate development of preventive and supportive therapies for cancer patients.

1 January 2026 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
CSChristina Stelzl
Christina Stelzl
ALAda Lerma-Clavero
Ada Lerma-Clavero
SCSelina Camenisch
Selina Camenisch
BSBenoit Simon
Benoit Simon
OEOlle Eriksson
Olle Eriksson
POPaul O'CAllaghan
Paul O'CAllaghan
In the CombiCTx assay, drugs diffuse from reservoirs into a surrounding gel and expose tumor cells to overlapping dynamic drug gradients, and cell responses can be monitored by time-lapse microscopy.